| Previous Close | 0.0706 |
| Open | 0.0615 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 0.0615 - 0.0800 |
| 52 Week Range | 0.0410 - 0.2820 |
| Volume | 87,406 |
| Avg. Volume | 200,917 |
| Market Cap | 20.263M |
| Beta (3Y Monthly) | 3.25 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.02 |
| Earnings Date | Nov 14, 2018 - Nov 19, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
SmallCapVoice.com, Inc. (SCV) and BioCorRx Inc. (BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of substance use disorders, announced today that a new audio interview with the Company is now available. Brady Granier called in to SmallCapVoice.com, Inc. to discuss the progress the Company has made in several key areas, the operational outlook for 2019, the launch of a new weight loss program and more. BioCorRx, Inc. issued a third quarter business update in November outlining where the Company stands with NIDA on their grant application process.
ANAHEIM, CA, Nov. 14, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – BioCorRx, Inc. (BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use disorders, today provided a business update for the third quarter ended September 30, 2018. Brady Granier, CEO, President, and Director of BioCorRx, Inc., stated, “We continue to work on the advancement of BICX102, a sustained release naltrexone implant for the treatment of opioid and alcohol use disorders. In early October, we received a Just-In-Time (JIT) request from NIDA on our grant application submitted in May of this year.
BioCorRx Inc. (OTCQB: BICX) (the "Company") is a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions. President, CEO, and Director of BioCorRx Inc, Brady Granier talked with Stock Day’s Everett Jolly about exciting developments at the company. Jolly asked for a general explanation of what it is that BioCorRx Inc. does to help fight addiction.
ANAHEIM, CA, Oct. 19, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- BioCorRx Inc. (BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today announced that the Company’s R&D subsidiary, BioCorRx Pharmaceuticals, has acquired a portfolio of six Therakine Biodelivery GmbH patent families that broadly cover sustained release delivery platforms for the local delivery of biologic and small molecule drugs. The portfolio includes issued patents and several pending patent applications which relate to BICX101, an injectable, sustained release naltrexone for the treatment of opioid and alcohol use disorders.
NEW YORK, NY / ACCESSWIRE / March 20, 2018 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has issued ...